Hemanext is a member of SCDAA’s SCD C.A.R.E.S. Consortium. Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving transfusion therapy. Visit their website to learn more about the company.

Follow Hemanext on social media


The SCD C.A.R.E.S. Consortium aims to change the perception of clinical trials and increase the participation of sickle cell patients in clinical trials to ultimately provide more therapies to the SCD community. Together, the consortium works together to educate and encourage more trial participation while providing opportunities and better options for the treatment of sickle cell disease.

←Return to the SCD C.A.R.E.S. Hub